Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 628

Document Document Title
WO/2022/125735A1
The disclosure provides processes for preparing the compound of formula (VIII) and pharmaceutically acceptable salts thereof. Intermediates useful in preparing the compound of formula (VIII) are also provided.  
WO/2022/094711A1
Disclosed is a process of preparation of a compound of formula 13, and intermediates prepared and used in the preparation of the compound of formula 13.  
WO/2022/078487A1
The present disclosure provides a zolinose compound represented by formula (I), a preparation method therefor and a use thereof, wherein definitions of substituents are provided in the description. The zolinose compound has application p...  
WO/2022/007838A1
A method for preparing glucopyranosyl derivatives as sodium dependent glucose cotransporter (SGLT) inhibitors, an intermediate thereof, and a method for preparing the intermediate. The method has simple operation, simple post-treatment, ...  
WO/2021/216427A1
Provided herein are nucleotide prodrug compounds, their preparation and their uses, such as treating diseases or conditions of a viral infection.  
WO/2021/216722A1
The present invention provides stereoselective processes of manufacture for the phosphoramidate nucleotide Compound 1 or a pharmaceutically acceptable salt thereof.  
WO/2021/121270A1
A method for purifying an SGLTs inhibitor and an application thereof. The SGLTs inhibitor is (1S,2S,3S,4R,5S)-5-(3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl) methyl)-4- ethyl phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3, 4-tri...  
WO/2021/095741A1
Provided is a cryoprotectant capable of inhibiting cytotoxicity, even in the presence of a cryoprotectant such as DMSO. Specifically provided is a compound represented by formula I-1 or I-2, or a salt or a solvate thereof. [In the form...  
WO/2021/074211A1
Described is a compound having the structure (I), (II) or (V), Formulae(I), (II), (V), wherein R1 is –H, –CH2OH or –CH(OH)CH2OH; R2 is –H, -OH, or –CH2OH; R3 is –H, -OH, or –CH2OH; n is 0 or 1; p is 0 or 1; R10 is hydrogen ...  
WO/2021/076630A1
In certain embodiments a platform technology for the facilitating immune therapy in the treatement of cancer is provided. In certain embodiments nanocarriers are provided that facilitate delivery of an IDO inhibitor in conjunction with a...  
WO/2021/015622A1
The current invention concerns methods for the synthesis of 6-azido-6-deoxy-2-N-acetyl-monosaccharide-nucleoside diphosphate, in particular 6-azido-6-deoxy-2-N-acetyl-D- galactosamine-nucleoside diphosphate or 6-azido-6-deoxy-2-N-acetyl-...  
WO/2021/004498A1
It relates to glucopyranosyl derivative of formula (I) as a sodium-dependent glucose transporters1 (SGLT1) inhibitor, a pharmaceutically acceptable salt, or a stereoisomer thereof, and further relates to a pharmaceutical composition cont...  
WO/2020/248068A1
The present application provides a synthetic method for production of 3-azido-3-deoxy-D-galactopyranose. Also provided are methods of using the 3-azido-3-deoxy-D-galactopyranose in the manufacture of galactoside galectin antagonists, suc...  
WO/2020/143653A1
Provided are a preparation method for a glucopyranosyl derivative compound used as an inhibitor of a sodium-dependent glucose transporter (SGLT) and an important intermediate of the glucopyranosyl derivative compound. The preparation met...  
WO/2020/001812A1
The present invention relates to a novel process for the preparation of SGLT-2 inhibitors via addition of a hydroxymethylene group in an open chain intermediate, readily accessible from D-glucose.  
WO/2019/224172A1
The present invention relates to the manufacture of allofuranose from glucofuranose as defined in the description and in the claim. Allofuranos is an intermediate in the manufacture of oligonucleotides which can be used as a medicament.  
WO/2019/221752A1
This invention relates to a method for inhibiting egg yolk gelation resulting from freezing and thawing. This method comprises treating egg yolk with an effective amount of a compound selected from the group consisting of amino acids, hy...  
WO/2019/179325A1
The present invention relates to the field of carbohydrate chemistry, and discloses a preparation method for a surface capsular polysaccharide structural derivative of Gram-positive bacteria. In the present invention, glucose is used as ...  
WO/2019/169988A1
The present invention relates to the field of pharmaceutical chemistry, and in particular, to the crystal forms of Ertugliflozin and preparation methods therefor. Said crystal form is crystal form I, crystal form II or crystal form III, ...  
WO/2019/149178A1
The present invention relates to a glucopyranosyl derivative and a use thereof. In particular, the present invention relates to a glucopyranosyl derivative that is used as an inhibitor of sodium-dependent glucose transporters (SGLTs), pa...  
WO/2019/119117A1
There are provided compounds of Formula (A) and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for the prevention or treatment in a mammal of joint and bone disorders such as arthritis...  
WO/2019/053700A2
Probe embodiments for identifying analytes involved in biofuel or bioenergy production, bioremediation, or nutrient cycling as well as methods of making and use are described herein. In some embodiments, probes identifying cellulose degr...  
WO/2018/074926A1
The present invention relates to new bi-functional and polyfunctional bis- dioxolanes and bis-dioxanes. The present inventors have established that the bis- dioxolanes and bis-dioxanes of the invention are highly advantageous as building...  
WO/2018/055496A1
The present invention relates to a process for the preparation of crystalline Form G1 of Ertugliflozin (1). (I) The invention also relates to crystalline Form G l obtained by the process of the present invention, the said Form Gl being s...  
WO/2017/190568A1
Disclosed are an amine solvate of a sodium-glucose linked transporter (SGLT) inhibitor, and a preparation method and application thereof. The SGLT inhibitor is (1S,2S,3S,4R,5S)-5-(3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl) methyl)-4-ethylb...  
WO/2017/178513A1
The present invention relates to a method for preparing monomers via depolymerisation from lignocellulose-containing biomass.  
WO/2017/134606A1
The present invention relates to a crystalline Form B of {(1 R,2S,3S,4R,5S)-5-[4-chloro-3-(4-ethoxybenzylphenyl]- 2,3,4-trihydroxy- 6,8-dioxabicyclo [3.2. 1]oct-1-yl}methyl acetate of Formula (II) and a process for its preparation. The p...  
WO/2017/088839A1
This present invention relates to a complex of a glucopyranosyl derivative and L-pyroglutamic acid as a sodium dependent glucose cotransporter (SGLT) inhibitor, and preparation processes thereof, and a pharmaceutical composition containi...  
WO/2017/085144A1
The invention relates to new compounds of formulae: Wherein: R 1 and R 2 can be independently H; a C 1 to C 6 alkyl including methyl, ethyl, propyl, butyl; aryl including phenyl, para-methoxyphenyl; or R 1, R 2 together with the carbon C...  
WO/2017/047816A1
The present invention provides a method for producing guanidine crosslinked artificial nucleic acid (abbreviated hereinafter as GuNA), and an intermediate compound for the production thereof. Specifically, the present invention provides ...  
WO/2017/034004A1
[Problem] To provide a novel gelling agent containing a sugar derivative. [Solution] A gelling agent comprising a compound represented by the formula (1) or (2). (in the formulae: R1 represents a C9-20 straight or branched alkyl, a C13-2...  
WO/2016/173425A1
This present invention relates to a glucopyranosyl derivative as sodium dependent glucose cotransporters (SGLTs) inhibitor, preparation processes thereof, and pharmaceutical uses thereof, pharmaceutical compositions containing the compou...  
WO/2016/050134A1
Provided are an L-proline compound of a sodium-glucose cotransporter 2 inhibitor, and a monohydrate and a crystal of the L-proline compound. Specifically, provided are 1,6-dehydrated-1-C{4-chloro-3-[(3-fluoro-4-ethoxyphenyl)meth yl]pheny...  
WO/2016/000599A1
Disclosed are a C-benzo five-membered heteroaromatic ring aryl glucoside derivative represented by general formula (I), a preparation method for the derivative or an intermediate thereof, and a use of the derivative, wherein R, R1, R2, R...  
WO/2015/137838A1
A compound of formula I : or a salt thereof, wherein: R1 is -OC(H) (X) (CH2)nC(=O)OH; R2 is -OH, -N3, or -N (H) C (=O) CH3; or R1 and R2 together with the carbon atoms to which they are attached form R3 is -H, -CH3, -CH2C(=O)OH, or -CH2O...  
WO/2015/109049A1
Provided herein are glycomimetic E-selectin antagonist compounds of formula (I)) and pharmaceutical compositions comprising at least one of the same. The compounds of the present disclosure include trisaccharide domain mimics comprising ...  
WO/2015/043473A1
Provided herein are glucopyranosyl derivatives used as sodium dependent glucose cotransporters (SGLTs) inhibitors and pharmaceutical uses thereof, particularly 6,8-dioxabicyclo [3.2.1] octane derivatives represented by Formula (I), or ph...  
WO/2015/032272A1
The present invention relates to a C-aryl glucoside derivative, a preparation method for same, and medical applications thereof. Specifically, the present invention relates to compounds as represented by formula I, and, tautomers, enanti...  
WO/2015/027963A1
The present invention relates to an aromatic ring derivative, and pharmaceutical composition and use thereof, in particular to aromatic ring derivatives or hydrates as represented by general formula (II), solvates, stereoisomers thereof,...  
WO/2014/132468A1
Provided is a sugar chain compound as mentioned in item (a) or (b), which contains a 1,2-cis-type sugar residue: (a) a polysaccharide or oligosaccharide formed by repeatedly binding a sugar unit represented by formula (I) or (I'); and (b...  
WO/2014/125967A1
The present invention addresses the problem of providing a highly-versatile method for easily producing α-O-pyranosides with a high degree of selectivity without establishing severe reaction conditions, and a pyranose donor used in said...  
WO/2014/094544A1
Provided are a phenyl C-glucoside derivative containing a deoxyglucose structure as represented by formula I, preparation method thereof, pharmaceutical composition containing same, and uses thereof in the preparation of drugs for treati...  
WO/2014/067003A1
The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also prov...  
WO/2014/013181A1
The invention relates to a thiophene derivative of the following general formula (I) or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically acceptable salt thereof, and the use of same as a med...  
WO/2013/178064A1
Disclosed are a substituted pyranol derivative with sodium dependent glucose transporters (SGLTs) inhibitor compound 4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl, a preparation method thereof, and a pharmaceutical application thereof; and p...  
WO/2013/172239A1
The present invention is an acid diffusion control agent consisting of at least one compound selected from among the group consisting of a compound represented by formula (1) and a compound represented by formula (2). In formula (1), R2 ...  
WO/2013/152359A1
Provided herein, inter alia, are compositions and methods of synthesis and detection of tetrazines and diazonorcaradienes.  
WO/2013/133419A1
[Problem] To provide a novel gelling agent that includes a sugar derivative. [Solution] A gelling agent comprising a compound represented by formula (1) or (2) (wherein R1 and R3 each independently represent a C1-20 straight-chain or bra...  
WO/2013/123896A1
Provided is a method for preparing 3-O-benzyl-1,2-O-isopropylidene-α-L-furan idose, which comprises: (1) protecting hydroxyl of 3-O-benzyl-1,2-O-isopropylidene-α-D-glucofuranose (III) by benzoyl and methylsulfonyl to obtain 6-O-benzoyl...  
WO/2013/097042A1
Disclosed is a compound of formula 1, as shown below, where R1, R2, R3, R4, R5, R6 and R7 are as described herein. Also, disclosed is a process for the preparation of compounds of formula 1, and intermediates used therein. The compound o...  

Matches 1 - 50 out of 628